Epitalon vs NAD+: how the two longevity peptides compare

Last updated 2026-07-26

What is the actual difference between epitalon and NAD+?

Epitalon (also spelled epithalon or epithalone) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, developed from research on the pineal gland peptide epithalamin by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology ^[1]. It's studied almost entirely for its proposed effect on telomerase activity and pineal gland regulation of melatonin secretion. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme every human cell already makes and uses, mainly for redox reactions in mitochondrial energy metabolism and as a substrate for enzymes like sirtuins and PARPs. It's not a novel molecule someone invented; it's something your cells run out of as you age, with tissue NAD+ levels dropping with age in multiple animal and some human studies ^[2]. So the comparison isn't really apples to apples. Epitalon is a lab-made short peptide with a narrow, specific hypothesis behind it (telomerase induction). NAD+ is a ubiquitous metabolic cofactor with a much broader mechanistic story and a much bigger, more mainstream research budget behind it. If you're evaluating them as "longevity compounds," you're evaluating two different categories of intervention that happen to both get marketed under the same anti-aging umbrella. For a fuller rundown of epitalon's mechanism and evidence base, see epithalon.

What does the actual human evidence look like for each?

This is where the comparison gets uncomfortable for epitalon. The core human data comes from a handful of trials run by Khavinson's own institute, mostly in elderly Russian and Ukrainian cohorts, published in Russian-language or lower-tier journals, and not independently replicated by labs outside that group ^[1][3]. A widely cited 2003 paper reported that epithalon-treated patients in a small cohort had lower cancer incidence and mortality over about six years of follow-up compared to controls, but the study wasn't a large randomized multicenter trial by modern standards, and no outside group has reproduced the mortality finding ^[3]. NAD+ has actual industry-sponsored and academic human trials, though they mostly measure blood NAD+ levels, muscle function, or inflammatory markers over weeks to months, not lifespan. A 2018 randomized controlled trial of the NAD+ precursor nicotinamide riboside (NR) in healthy middle-aged and older adults found it safely raised NAD+ metabolome levels in blood but did not significantly change insulin sensitivity, blood lipids, or several other metabolic markers over 12 weeks ^[4]. Other trials of nicotinamide mononucleotide (NMN) in humans have shown modest improvements in walking speed or muscle-related measures in small older-adult cohorts, but sample sizes tend to run in the dozens, not thousands ^[5]. Neither compound has a completed, published, randomized trial showing extended human lifespan. That's true for essentially every longevity compound on the market right now, so it's not unique to epitalon. What's different is the transparency and volume of independent data: NAD+ precursor research is published across many labs and countries and in mainstream journals like Nature Communications and Cell Metabolism; epitalon's headline claims trace back overwhelmingly to one Russian research group.

What do animal studies show for telomerase and lifespan?

Epitalon's telomerase story rests mostly on rodent and cell culture work. Khavinson's group and collaborators reported that epithalon increased telomerase activity in human somatic cells in culture and extended lifespan in several mouse and rat strains, including one widely cited paper on female SHR mice showing increased mean lifespan with epithalon treatment ^[1][6]. These are legitimate published findings, but they're animal and cell-line data, not human outcomes, and the strain-specific, small-cohort nature of rodent lifespan studies makes them easy to over-interpret. NAD+ precursor research in mice has a wider footprint. Multiple independent labs, more than one group, have published mouse studies where NMN or NR supplementation improved mitochondrial function, insulin sensitivity, and in some studies modestly extended lifespan or healthspan measures in aged mice . The mechanistic story (declining NAD+ with age impairing sirtuin and PARP function) is now taught in mainstream biochemistry and gerontology courses, which tells you something about how mainstream the underlying biology has become even though the human translation is still unproven. Bottom line for animal data: both have real, published rodent findings behind them. NAD+ precursor research has been replicated across more independent labs; epitalon's lifespan claims are more concentrated in work tied to the original Russian institute.

How do the delivery methods and dosing compare?

Epitalon is typically used as a subcutaneous injection, most commonly in 10-20 day cycles at doses in the 5-10mg per day range, based on the protocols described in the original Russian clinical studies and echoed across current retail dosing guides ^[1]. It's not something people take daily year-round; the cyclical dosing pattern is central to how it's used in the source literature. For actual dosing breakdowns and calculator tools, see epitalon dosage and the epitalon dosage calculator. Anyone actually injecting it should look at epitalon peptide injections for technique and handling. NAD+ comes in far more forms: IV infusion (typically 250-1000mg per session, run over hours in a clinic), intramuscular or subcutaneous injection, and oral precursors (NR or NMN capsules, usually 250-500mg daily). IV NAD+ is the most expensive and least studied route in terms of controlled trials; oral precursor supplementation is the route with the most actual randomized trial data behind it ^[4][5]. | Factor | Epitalon | NAD+ |

Are epitalon and NAD+ actually being compared for the same goal?

Not really, and that's worth saying plainly. People reach for epitalon hoping to influence telomere biology and, by extension, cellular aging at the chromosomal level. People reach for NAD+ hoping to restore mitochondrial energy metabolism, which shows up more immediately as fatigue, exercise capacity, or cognitive fog rather than a chromosomal aging story. If you're chasing a specific symptom (low energy, poor recovery, brain fog), NAD+ precursor research at least has some human data on metabolic markers to point to, even if it's short-term and modest. If you're chasing the telomere/telomerase hypothesis specifically, epitalon is closer to what you're looking for mechanistically, but you're relying on a much thinner and less independently verified evidence base to get there. Neither is a proven longevity intervention in humans. Both are being sold with language that outruns what the trials actually show.

What are the safety and side effect profiles?

Epitalon's published human studies report it as generally well tolerated at the doses used, with no major adverse events flagged in the Russian clinical cohorts, though these studies weren't designed or powered as safety trials in the way FDA Phase 1/2 studies are ^[1][3]. Independent safety data outside that research group is thin. Injection site reactions are the most commonly reported issue in real-world use. See epitalon side effects for a full breakdown. NAD+ has a longer safety track record simply because it's an endogenous molecule people have been giving as IV infusions in various clinical contexts for years, and oral NR has been through FDA-notified GRAS (Generally Recognized As Safe) determination for use in food, which involved company-submitted but FDA-reviewed safety data . Reported side effects for IV NAD+ include flushing, chest tightness, and nausea during infusion, particularly at faster infusion rates; oral NR and NMN report mostly mild GI symptoms in trials. Neither compound is FDA-approved as a drug for anti-aging or any other indication. Epitalon is not legally marketed as a dietary supplement in the US and exists in a research-chemical gray zone; NAD+ precursors like NR are sold as dietary supplements, which is a real regulatory difference buyers should understand, not a marketing footnote.

What does each one cost, and is the cost justified by the evidence?

Epitalon runs roughly $40-90 for a 10-20mg vial from research-chemical suppliers, translating to maybe $50-150 per 10-20 day cycle depending on dose and sourcing, though prices vary a lot by vendor and purity claims. NAD+ costs vary enormously by route. Oral NR or NMN supplements run around $30-80 per month at typical consumer doses. IV NAD+ infusions are dramatically more expensive: clinics commonly charge $150-600 or more per session, and protocols often call for multiple sessions, putting a monthly IV NAD+ habit well into four figures for some people. Neither price tag is justified by proven human lifespan or healthspan extension, because that data doesn't exist for either compound yet. If you're spending clinic-level money on IV NAD+ expecting proven anti-aging results, you're paying a premium for a mechanism story, not a completed outcome trial. If you're spending less on oral NAD+ precursors or on epitalon cycles, you're taking on lower financial risk but still buying into an unproven human outcome.

Can you take epitalon and NAD+ together, and does it make sense to?

Nothing in the literature suggests a direct pharmacological conflict between epitalon and NAD+ precursors, since they act through unrelated pathways (telomerase/pineal regulation versus cellular redox metabolism). Some people in longevity-focused communities stack the two on the theory that they're targeting different arms of the aging process. There's no published human trial testing the combination, so any claim about added benefit from stacking them is speculation, not evidence. If you're going to try both, the more defensible approach is to introduce them separately and track how you actually feel and any lab markers you're following (energy, sleep, injection site reactions), rather than starting both at once and losing the ability to tell what's doing what. Anyone considering either compound should talk to a physician familiar with peptide and NAD+ therapies, particularly given the injection route for epitalon and the lack of FDA oversight for compounded or research-chemical versions of either substance.

Where does the sourcing and quality control differ?

NAD+ precursors sold as dietary supplements (NR, NMN) go through the same general supplement manufacturing framework as other over-the-counter products, meaning third-party testing varies by brand but reputable companies publish certificates of analysis. IV NAD+ given in a clinic is typically compounded, which means quality depends heavily on the compounding pharmacy's standards, not FDA drug approval. Epitalon sits further out on the gray-market end: it's sold almost exclusively through research-chemical vendors, and purity, concentration, and even correct peptide identity vary widely between suppliers. Independent lab testing of research-chemical peptides has repeatedly found products with less active ingredient than labeled or in some cases the wrong peptide entirely, though this is a general research-chemical industry problem rather than something specific to epitalon. If you're going to use epitalon at all, sourcing matters more than for almost any other decision in this comparison. A provider-reviewed route, where a clinician oversees use and the product moves through a named, accountable pharmacy partner rather than an anonymous vendor, meaningfully reduces the odds of getting an underdosed or mislabeled product. Epitalon Rx connects users with exactly this kind of provider-reviewed pathway rather than selling raw vials directly. See buy epitalon for what a legitimate sourcing path actually looks like.

So which one should a longevity-focused reader actually consider?

If you want the intervention with more independent human data behind it, NAD+ precursors (specifically oral NR, which has the most RCT backing) are the more evidence-supported choice right now, even though the effect sizes shown so far are modest and short-term, not lifespan outcomes ^[4][5]. If you're specifically drawn to the telomerase/telomere-length hypothesis of aging and are comfortable with a thinner, less independently replicated evidence base concentrated in one research group's decades of work, epitalon is the compound built around that specific mechanism ^[1][3][6]. Just go in knowing the mortality and cancer-incidence claims trace back almost entirely to Khavinson's own institute and haven't been confirmed by outside labs running comparable trials. Neither is a substitute for the basics that actually have strong human trial data behind them for healthy aging: exercise, sleep, and diet quality. Treat both epitalon and NAD+ as speculative additions on top of that foundation, not replacements for it, and size your spending and risk tolerance accordingly.

Frequently asked questions

Is epitalon the same thing as epithalon?

Yes. Epitalon and epithalon (sometimes epithalone) refer to the same synthetic tetrapeptide, Ala-Glu-Asp-Gly, developed from pineal gland research by Vladimir Khavinson's group in St. Petersburg. The spelling varies by vendor and by translation from the original Russian literature, but the molecule is identical.

Does NAD+ have more human research than epitalon?

Yes, by volume and independence. NAD+ precursor trials (NR, NMN) have been run by multiple independent university and industry labs and published in mainstream journals. Epitalon's human data comes overwhelmingly from one Russian research institute, with essentially no large independent replication outside that group.

Which is cheaper, epitalon or NAD+?

Oral NAD+ precursors (NR, NMN) are usually the cheapest option at $30-80 per month. Epitalon cycles run roughly $50-150 per 10-20 day course depending on dose and vendor. IV NAD+ infusions are by far the most expensive route, often $150-600 or more per session.

Can epitalon actually lengthen telomeres in humans?

There's no confirmed human trial showing epitalon lengthens telomeres. The telomerase-activation evidence comes from cell culture and rodent studies out of Khavinson's group; a few small human cohort studies from the same institute report health outcomes like lower cancer incidence, but telomere length itself hasn't been directly and independently confirmed to change in people.

Is NAD+ FDA-approved for anti-aging?

No. NAD+ itself has no FDA approval for anti-aging or any indication. Nicotinamide riboside has received a GRAS (Generally Recognized As Safe) notification for use in food, which is a safety determination, not an efficacy approval for aging or disease.

Are there interactions between epitalon and NAD+?

No documented pharmacological interaction exists in the literature, since they work through unrelated pathways. There's also no published trial testing the combination in humans, so claims of added benefit from stacking them are speculative, not evidence-based. If trying both, introduce them separately to track effects.

Why is epitalon not sold as a dietary supplement in the US?

Epitalon is a synthetic peptide, not a vitamin, mineral, or botanical, and it doesn't fit the dietary supplement categories defined under US law. It's typically sold through research-chemical channels instead, which is part of why sourcing quality and purity vary so much between vendors.

Does IV NAD+ work better than oral NAD+ precursors?

There's no strong head-to-head human trial comparing IV NAD+ against oral NR or NMN for meaningful outcomes. IV infusion raises blood NAD+ faster and costs far more per session. Oral precursors have more randomized trial data behind them, even though the trials mostly measure blood levels and metabolic markers, not aging outcomes.

What is the strongest evidence against epitalon's anti-aging claims?

The main gap is independent replication. Nearly all of the mortality, cancer-incidence, and telomerase findings trace back to Vladimir Khavinson's institute in St. Petersburg. No large independent lab or pharmaceutical trial outside that group has replicated the human mortality claims, which is a significant red flag for a compound marketed this aggressively.

Is epitalon legal to buy and use in the United States?

Epitalon is not FDA-approved as a drug and is not legally marketed as a dietary supplement, so it exists in a research-chemical gray zone. It's typically sold labeled 'not for human consumption' by research-chemical vendors. A provider-reviewed sourcing path through a licensed pharmacy partner is a materially different, more accountable option than anonymous vendor purchases.

Do NAD+ supplements actually increase cellular NAD+ levels in humans?

Yes, this part is fairly well established. Randomized trials of nicotinamide riboside have shown it reliably raises the blood NAD+ metabolome in humans within weeks. What hasn't been established is that this rise translates into meaningful improvements in metabolic health, muscle function, or lifespan.

Which has better long-term safety data, epitalon or NAD+?

NAD+ has the better long-term safety picture, mainly because it's an endogenous molecule with years of IV clinical use and FDA-reviewed GRAS safety data for NR in food. Epitalon's safety data comes almost entirely from the original Russian clinical cohorts and lacks independent long-term follow-up outside that research group.

Sources

1. Khavinson VK et al., Bulletin of Experimental Biology and Medicine, review of Epithalon/Epithalamin research: Epitalon's origin from pineal peptide research and reported telomerase activation in human cell culture
2. Verdin E., Science, NAD+ in aging, metabolism, and neurodegeneration: NAD+ levels decline with age and NAD+ acts as substrate for sirtuins and PARPs
3. Martens CR et al., Nature Communications, 2018, nicotinamide riboside RCT in healthy middle-aged and older adults: 12-week NR trial raised blood NAD+ metabolome but did not significantly improve insulin sensitivity or several metabolic markers
4. Igarashi M et al., NMN human trial, Cell Metabolism / related NMN clinical research summary: Small human trials of NMN reported modest improvements in walking speed and muscle-related measures in older adults
5. Anisimov VN et al., Peptide epithalon and mouse lifespan study: Epithalon extended mean lifespan in female mice in a rodent longevity study
6. NIH National Institute on Aging, research on NAD+ and aging interventions: Independent research on NAD+ precursors and mitochondrial function in aged mice across multiple labs